Table Talk: Beyond the breakthrough

In the world of personalized medicine, cell and gene therapy (CGT) developers understandably focus on the science. With their targeted use of living cells or genetic material to fight disease at the root cause, these treatments offer hope to patients with few, if any, other options. But a breakthrough is only the beginning.

To explore the many hurdles that manufacturers must overcome to bring a complex product to market, Joseph Rosano, Managing Director, CGT, Health Systems, sits down with two Cencora CGT experts: Mark Kelley, Senior Director, CGT Enterprise Partnerships, Account Management & Implementation, and Louis Cicchini, PhD, Senior Director, Scientific Affairs & Strategic Partnerships, CGT. Together, they discuss how developers can better navigate challenges like commercialization, value narrative, storage and distribution, and sites of care. Because a cure isn’t valuable if it doesn’t reach the people who need it most.